The Pricing Dilemma

A biotech startup developed a treatment for a rare disease affecting 5,000 people worldwide. Research and development cost €800 million over twelve years. To recover costs and fund future research, they priced the treatment at €300,000 per patient. Patient advocacy groups called it "profiteering from suffering." The CEO responded: "If we don't recover our costs, we go bankrupt, and the next ten drugs we're developing never exist. Those drugs could save millions." Insurance companies refused to cover it. Some patients sold their homes. Others started crowdfunding campaigns. A generic version could be produced for €500 per dose, but patent law prevents it for another eight years.

The Algorithm Problem

A hiring platform used AI to screen job applications. After two years, an internal audit discovered the algorithm was rejecting 73% of female applicants for technical roles — not because it was programmed to discriminate, but because it had learned from ten years of hiring data in which men were overwhelmingly selected. The company faced a choice: keep the efficient algorithm and risk discrimination charges, retrain it with corrected data which would take six months and cost €2 million, or return to human screening which was slower and also had proven biases. Their investors said: "Fix it quietly and don't tell anyone." Their ethics officer said: "We must disclose publicly."

The Whistleblower's Price

A senior engineer at an automotive company discovered that the emissions software was programmed to cheat during testing — showing lower pollution numbers than the car actually produced. She reported it internally. Her manager told her to "focus on her own projects." She reported it to the regulator. The company was fined €4 billion. Three executives went to prison. But the engineer was blacklisted by the industry. No company would hire her. She lost her home and went through a divorce. Seven years later, she was given an ethics award but still could not find a job in her field. She told a journalist: "I would do it again. But I wish someone had warned me what doing the right thing actually costs."

The Data Trade

A health app with 30 million users collected detailed wellness data — exercise, sleep, heart rate, mood. The privacy policy stated data would be used "to improve the service." The company sold anonymised data to pharmaceutical companies who used it to identify potential customers for new drugs. Technically, no law was broken. The data was anonymised. But a research team demonstrated that 87% of "anonymised" users could be re-identified by cross-referencing with public records. When a journalist exposed the story, the CEO said: "We never sold personal data. We sold patterns." Users said: "You sold us."